Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin

Blood

Volumn 131, Issue 8, 2018, Pages 899-910

  Aschemeyer, Sharraya ^a   Qiao, Bo ^a   Stefanova, Deborah ^a   Valore, Erika V ^a   Sek, Albert C ^a   Alex Ruwe, T ^b   Vieth, Kyle R ^b   Jung, Grace ^a   Casu, Carla ^c   Rivella, Stefano ^c   Jormakka, Mika ^d,e   Mackenzie, Bryan ^b   Ganz, Tomas ^a   Nemeth, Elizabeta ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^d UNIVERSITY OF SYDNEY   (Australia)

^e University of Sydney   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; FERROPORTIN; HEPCIDIN; IRON; CATION TRANSPORT PROTEIN; METAL TRANSPORTING PROTEIN 1; PROTEIN BINDING;

ALPHA HELIX; ANIMAL EXPERIMENT; ARTICLE; BIOTINYLATION; CELLULAR DISTRIBUTION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG PROTEIN BINDING; ENDOCYTOSIS; ERYTHROCYTE; ERYTHROCYTE CONCENTRATE; HEK293 CELL LINE; HEK293T CELL LINE; HUMAN; HUMAN CELL; IRON TRANSPORT; MOUSE; NONHUMAN; OOCYTE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN STRUCTURE; SITE DIRECTED MUTAGENESIS; UBIQUITINATION; WESTERN BLOTTING; WILD TYPE; XENOPUS; AGONISTS; ANIMAL; BINDING SITE; C57BL MOUSE; CELL CULTURE; CHEMISTRY; COMPUTER SIMULATION; CYTOLOGY; DRUG RESISTANCE; GENETICS; METABOLISM; MUTATION; PROTEIN CONFORMATION; PROTEIN DOMAIN; STRUCTURE ACTIVITY RELATION; XENOPUS LAEVIS;

ANIMALS; BINDING SITES; CATION TRANSPORT PROTEINS; CELLS, CULTURED; COMPUTER SIMULATION; DRUG RESISTANCE; ENDOCYTOSIS; HEK293 CELLS; HEPCIDINS; HUMANS; IRON; MICE; MICE, INBRED C57BL; MUTAGENESIS, SITE-DIRECTED; MUTATION; OOCYTES; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DOMAINS; STRUCTURE-ACTIVITY RELATIONSHIP; UBIQUITINATION; XENOPUS LAEVIS;

EID: 85042423560     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2017-05-786590     Document Type: Article

References (49)

1. Drakesmith H, Nemeth E, Ganz T. Ironing out ferroportin. Cell Metab. 2015;22(5):777-787.
2. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306(5704): 2090-2093.
3. Qiao B, Sugianto P, Fung E, et al. Hepcidin-induced endocytosis of ferroportin is dependent on ferroportin ubiquitination. Cell Metab. 2012;15(6):918-924.
4. Preza GC, Pinon R, Ganz T, Nemeth E. Cellular catabolism of the iron-regulatory peptide hormone hepcidin. PLoS One. 2013;8(3): e58934.
5. De Falco L, Sanchez M, Silvestri L, et al. Iron refractory iron deficiency anemia. Haematologica. 2013;98(6):845-853.
6. Fraenkel PG. Anemia of inflammation: a review. Med Clin North Am. 2017;101(2): 285-296.
7. Pietrangelo A. Hereditary hemochromatosis–a new look at an old disease. N Engl J Med. 2004;350(23):2383-2397.
8. Origa R. b-Thalassemia. Genet Med. 2017; 19(6):609-619.
9. Pietrangelo A. The ferroportin disease. Blood Cells Mol Dis. 2004;32(1):131-138.
10. Schimanski LM, Drakesmith H, Merryweather-Clarke AT, et al. In vitro functional analysis of human ferroportin (FPN) and hemochromatosis-associated FPN mutations. Blood. 2005;105(10):4096-4102.
11. Lok CY, Merryweather-Clarke AT, Viprakasit V, et al. Iron overload in the Asian community. Blood. 2009;114(1):20-25.
12. Sham RL, Phatak PD, West C, Lee P, Andrews C, Beutler E. Autosomal dominant hereditary hemochromatosis associated with a novel ferroportin mutation and unique clinical features. Blood Cells Mol Dis. 2005;34(2): 157-161.
13. Létocart E, Le Gac G, Majore S, et al. A novel missense mutation in SLC40A1 results in resistance to hepcidin and confirms the existence of two ferroportin-associated iron overload diseases. Br J Haematol. 2009; 147(3):379-385.
14. Callebaut I, Joubrel R, Pissard S, et al. Comprehensive functional annotation of 18 missense mutations found in suspected hemochromatosis type 4 patients. Hum Mol Genet. 2014;23(17):4479-4490.
15. Wallace DF, Clark RM, Harley HA, Subramaniam VN. Autosomal dominant iron overload due to a novel mutation of ferro-portin1 associated with parenchymal iron loading and cirrhosis. J Hepatol. 2004;40(4): 710-713.
16. Pelucchi S, Mariani R, Salvioni A, et al. Novel mutations of the ferroportin gene (SLC40A1): analysis of 56 consecutive patients with unexplained iron overload. Clin Genet. 2008; 73(2):171-178.
17. Rivard SR, Lanzara C, Grimard D, et al. Autosomal dominant reticuloendothelial iron overload (HFE type 4) due to a new missense mutation in the FERROPORTIN 1 gene (SLC11A3) in a large French-Canadian family. Haematologica. 2003;88(7):824-826.
18. Mayr R, Griffiths WJH, Hermann M, et al. Identification of mutations in SLC40A1 that affect ferroportin function and phenotype of human ferroportin iron overload. Gastroenterology. 2011;140(7):2056-2063. e1.
19. Yamakawa N, Oe K, Yukawa N, et al. A novel phenotype of a hereditary hemochromatosis type 4 with ferroportin-1 mutation, presenting with juvenile cataracts. Intern Med. 2016; 55(18):2697-2701.
20. Le Lan C, Mosser A, Ropert M, et al. Sex and acquired cofactors determine phenotypes of ferroportin disease. Gastroenterology. 2011; 140(4):1199-1207.e1-2.
21. Santos PC, Cancado RD, Pereira AC, et al. Hereditary hemochromatosis: mutations in genes involved in iron homeostasis in Brazilian patients. Blood Cells Mol Dis. 2011;46(4): 302-307.
22. Zaahl MG, Merryweather-Clarke AT, Kotze MJ, van der Merwe S, Warnich L, Robson KJ. Analysis of genes implicated in iron regulation in individuals presenting with primary iron overload. Hum Genet. 2004;115(4):409-417.
23. Lee PL, Gaasterland T, Barton JC. Mild iron overload in an African American man with SLC40A1 D270V. Acta Haematol. 2012; 128(1):28-32.
24. Wallace DF, Dixon JL, Ramm GA, Anderson GJ, Powell LW, Subramaniam VN. A novel mutation in ferroportin implicated in iron overload. J Hepatol. 2007;46(5):921-926.
25. Rice AE, Mendez MJ, Hokanson CA, Rees DC, Björkman PJ. Investigation of the biophysical and cell biological properties of ferroportin, a multipass integral membrane protein iron exporter. J Mol Biol. 2009;386(3):717-732.
26. Drakesmith H, Schimanski LM, Ormerod E, et al. Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin. Blood. 2005;106(3):1092-1097.
27. Fernandes A, Preza GC, Phung Y, et al. The molecular basis of hepcidin-resistant hereditary hemochromatosis. Blood. 2009;114(2):437-443.
28. Wallace DF, Harris JM, Subramaniam VN. Functional analysis and theoretical modeling of ferroportin reveals clustering of mutations according to phenotype. Am J Physiol Cell Physiol. 2010;298(1):C75-C84.
29. Détivaud L, Island ML, Jouanolle AM, et al. Ferroportin diseases: functional studies, a link between genetic and clinical phenotype. Hum Mutat. 2013;34(11):1529-1536.
30. Liu XB, Yang F, Haile DJ. Functional consequences of ferroportin 1 mutations. Blood Cells Mol Dis. 2005;35(1):33-46.
31. Le Gac G, Ka C, Joubrel R, et al. Structure-function analysis of the human ferroportin iron exporter (SLC40A1): effect of hemochromatosis type 4 disease mutations and identification of critical residues. Hum Mutat. 2013; 34(10):1371-1380.
32. Bonaccorsi di Patti MC, Polticelli F, Cece G, et al. A structural model of human ferroportin and of its iron binding site. FEBS J. 2014; 281(12):2851-2860.
33. Taniguchi R, Kato HE, Font J, et al. Outward- and inward-facing structures of a putative bacterial transition-metal transporter with homology to ferroportin. Nat Commun. 2015; 6:8545.
34. Hilton KB, Lambert LA. Molecular evolution and characterization of hepcidin gene products in vertebrates. Gene. 2008;415(1-2): 40-48.
35. Roy A, Kucukural A, Zhang Y. I-TASSER: a unified platform for automated protein structure and function prediction. Nat Protoc. 2010;5(4):725-738.
36. Yang J, Yan R, Roy A, Xu D, Poisson J, Zhang Y. The I-TASSER Suite: protein structure and function prediction. Nat Methods. 2015;12(1):7-8.
37. Mitchell CJ, Shawki A, Ganz T, Nemeth E, Mackenzie B. Functional properties of human ferroportin, a cellular iron exporter reactive also with cobalt and zinc. Am J Physiol Cell Physiol. 2014;306(5):C450-C459.
38. Stefanova D, Raychev A, Arezes J, et al. Endogenous hepcidin and its agonist mediate resistance to selected infections by clearing non-transferrin-bound iron. Blood. 2017; 130(3):245-257.
39. Casu C, Oikonomidou PR, Chen H, et al. Minihepcidin peptides as disease modifiers in mice affected by b-thalassemia and poly-cythemia vera. Blood. 2016;128(2):265-276.
40. Preza GC, Ruchala P, Pinon R, et al. Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload. J Clin Invest. 2011;121(12): 4880-4888.
41. Fung E, Chua K, Ganz T, Nemeth E, Ruchala P. Thiol-derivatized minihepcidins retain biological activity. Bioorg Med Chem Lett. 2015;25(4):763-766.
42. Zhang D-L, Wang J, Shah B, et al. Ferroportin protects red blood cells from oxidative stress and malaria infection by exporting free intracellular iron. Abstract from the Seventh Congress of the International BioIron Society (IBIS) Biennial World Meeting (BioIron 2017); 7-11 May 2017; Los Angeles, CA.
43. Chaston T, Chung B, Mascarenhas M, et al. Evidence for differential effects of hepcidin in macrophages and intestinal epithelial cells. Gut. 2008;57(3):374-382.
44. Chung B, Chaston T, Marks J, Srai SK, Sharp PA. Hepcidin decreases iron transporter expression in vivo in mouse duodenum and spleen and in vitro in THP-1 macrophages and intestinal Caco-2 cells. J Nutr. 2009;139(8): 1457-1462.
45. Zhang DL, Senecal T, Ghosh MC, Ollivierre-Wilson H, Tu T, Rouault TA. Hepcidin regulates ferroportin expression and intracellular iron homeostasis of erythroblasts. Blood. 2011;118(10):2868-2877.
46. Harrison-Findik DD, Schafer D, Klein E, et al. Alcohol metabolism-mediated oxidative stress down-regulates hepcidin transcription and leads to increased duodenal iron transporter expression. J Biol Chem. 2006;281(32): 22974-22982.
47. Olynyk JK, Knuiman MW, Divitini ML, Bartholomew HC, Cullen DJ, Powell LW. Effects of HFE gene mutations and alcohol on iron status, liver biochemistry and morbidity. J Gastroenterol Hepatol. 2005;20(9): 1435-1441.
48. Praschberger R, Schranz M, Griffiths WJ, et al. Impact of D181V and A69T on the function of ferroportin as an iron export pump and hepcidin receptor. Biochim Biophys Acta. 2014; 1842(9):1406-1412.
49. Ferbo L, Manzini PM, Badar S, et al. Detection of a rare mutation in the ferroportin gene through targeted next generation sequencing. Blood Transfus. 2016;14(6): 531-534.